Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D55B | ISIN: US64134X2018 | Ticker-Symbol:
NASDAQ
27.06.25 | 21:59
2,500 US-Dollar
-1,77 % -0,045
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
NEURAXIS INC Chart 1 Jahr
5-Tage-Chart
NEURAXIS INC 5-Tage-Chart

Aktuelle News zur NEURAXIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.06.NeurAxis, Inc.: NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives1
NEURAXIS Aktie jetzt für 0€ handeln
16.06.Craig-Hallum initiates NeurAxis stock with buy rating on pediatric device3
10.06.NeurAxis, Inc.: NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS1
04.06.Neuraxis, INC - 8-K, Current Report2
22.05.NeurAxis, Inc.: NeurAxis Announces Closing of $5.0 Million Registered Direct Offering3
21.05.Neuraxis, INC - 8-K, Current Report1
21.05.NeurAxis To Sell About 1.5 Mln Stock At $3.25/shr; Stock Plunges In Pre-market-
21.05.NeurAxis slides 21%, raises $5M via stock1
21.05.NeurAxis, Inc.: NeurAxis Announces $5.0 Million Registered Direct Offering1
20.05.NeurAxis Stock Surges On FDA Clearance For IB-Stim In Pediatric Functional Dyspepsia Treatment-
12.05.NeurAxis GAAP EPS of -$0.33, revenue of $0.89M1
12.05.NeurAxis GAAP EPS of -$0.33, revenue of $0.90M misses by $724.1M14
12.05.NeurAxis, Inc.: NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues674CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
► Artikel lesen
12.05.Neuraxis, INC - 10-Q, Quarterly Report-
05.05.NeurAxis, Inc.: NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 20251
15.04.NeurAxis, Inc.: NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 20253
22.03.NeurAxis, Inc. (NASDAQ:NRXS) Q4 2024 Earnings Call Transcript1
20.03.NeurAxis Better on Q4 Results1
20.03.NeurAxis reports Q4 results1
20.03.NeurAxis, Inc.: NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues289CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
► Artikel lesen
Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1